Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2024-05-10 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
113年4月營業收入
Interim / Quarterly Report Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 杏輝, presented in a tabular format with explanations about accounting standards and reporting practices. It contains actual financial data for a specific month (April 2024) and compares it to the previous year. The document length is short (768 characters) but it includes substantive financial data, not just an announcement or a link to a report. It is not a full annual or interim report but rather a periodic financial summary. Given the presence of actual financial figures and the nature of the data, this fits best as an Interim / Quarterly Report (IR).
2024-05-10 Chinese
113年04月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, chairpersons, general managers, and their family members. It shows changes in shareholdings, including increases and decreases, and categorizes shares by type and ownership status. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement about voting or dividends. The document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is substantial and contains actual data, not just an announcement or certification, so it is not RNS or RPA.
2024-05-07 Chinese
113年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, supervisors, and senior management, with specific numbers of shares held, pledged shares, and related party holdings. The content focuses on insider shareholdings and changes, which is characteristic of a Director's Dealing report. There is no indication of financial statements, earnings data, or meeting materials. The document length is under 5,000 characters and is a direct disclosure of insider shareholdings rather than an announcement or summary. Therefore, the document fits best into the Director's Dealing (DIRS) category.
2024-05-07 Chinese
本公司依公開發行公司資金貸與及背書保證處理準則 第二十五條第一項第四款規定公告
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from a publicly listed company (杏輝) regarding the provision of guarantees and endorsements for a subsidiary company. It includes specific financial figures related to the guarantee limits, outstanding balances, and related financial ratios. The document references compliance with a specific regulatory guideline (公開發行公司資金貸與及背書保證處理準則) and provides detailed disclosure of the guarantee transaction. The document length is short (1132 characters) and it is not a report or financial statement but a regulatory disclosure about a financing-related guarantee. This fits the category of Capital/Financing Update (CAP) as it concerns financing activities and guarantees provided by the company.
2024-05-06 Chinese
公告本公司獨立董事任期達三屆繼續提名之說明
Board/Management Information Classification · 95% confidence The document is a public announcement from a listed company regarding the continued nomination of an independent director who has served three terms. It references compliance with regulations about independent directors and provides reasons for the nomination continuation. There is no financial data, no report attached or referenced, and the content is about board/management information specifically related to director nomination and tenure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or announcement of voting results.
2024-05-06 Chinese
本公司董事會決議通過113年第1季合併財務報告案
Regulatory Filings Classification · 95% confidence The document is a brief announcement from the company's CFO regarding the board's approval of the consolidated financial report for the first quarter of the year 113 (likely a local calendar year). It includes summarized financial data such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity for the period 113/01/01 to 113/03/31. The document length is only 904 characters, which is quite short and resembles a regulatory announcement rather than a full interim or quarterly report. There is no detailed financial statement or substantive analysis, only key financial figures and approval dates. According to the rules, such short announcements with summarized financial data and board approval notices are classified as Regulatory Filings (RNS) rather than full Interim/Quarterly Reports (IR).
2024-05-06 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.